title: Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.
abstract: This is a review of the pharmacology of strontium ranelate (Protelos, Protos, Protaxos, Bivalos, Osseor), and its efficacy and tolerability in the treatment of patients with postmenopausal osteoporosis. Strontium ranelate is a divalent strontium salt of ranelic acid that is capable of increasing bone formation and reducing bone resorption, thereby uncoupling and rebalancing bone turnover in favour of bone formation. The drug is effective in reducing the risk of fractures, including both vertebral and nonvertebral fractures, in patients with postmenopausal osteoporosis, according to data from two large, double-blind, placebo-controlled, multicentre trials of 5 years' duration, and reduced the risk of hip fracture in high-risk patients in a post hoc analysis of one trial. Moreover, data from patients who continued to receive the drug during the 3-year extension phases of these trials indicate that strontium ranelate continues to provide protection against new vertebral fractures and nonvertebral fractures for up to 8 years of therapy. It also improves bone mineral density at numerous sites and both increases markers of bone formation and decreases markers of bone resorption. Strontium ranelate is administered orally as a suspension and is generally well tolerated. The nature of adverse events was generally similar regardless of treatment duration in clinical trials, with the most commonly reported being nausea and diarrhoea over 5 years of treatment, and memory loss and diarrhoea during longer-term treatment. Although an increased risk of venous thromboembolism was associated with strontium ranelate relative to placebo over 5 years of treatment in a pooled analysis of clinical trials, postmarketing data have not confirmed this finding. Overall, the clinical data available suggest that strontium ranelate is an effective and generally well tolerated option for the first-line treatment of postmenopausal osteoporosis.
authors.affiliation: Adis, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Emma D
authors.initials: ED
authors.lastname: Deeks
authors.forename: Sohita
authors.initials: S
authors.lastname: Dhillon
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D009942:Organometallic Compounds / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D013876:Thiophenes / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
references.citation: Bone. 1996 Jun;18(6):517-23
references.pmid: 8805991
references.citation: Bone. 2001 Aug;29(2):176-9
references.pmid: 11502480
references.citation: Osteoporos Int. 2010 Feb;21(2):339-49
references.pmid: 19513577
references.citation: Bone. 2008 Jun;42(6):1131-6
references.pmid: 18378206
references.citation: Osteoporos Int. 2010 Jan;21(1):157-65
references.pmid: 19350339
references.citation: Arthritis Rheum. 2008 Jun;58(6):1687-95
references.pmid: 18512789
references.citation: Bone. 2010 Feb;46(2):440-6
references.pmid: 19716940
references.citation: Rheumatology (Oxford). 2008 Jul;47 Suppl 4:iv17-19
references.pmid: 18556645
references.citation: J Bone Miner Res. 2006 Apr;21(4):536-42
references.pmid: 16598373
references.citation: Osteoporos Int. 2009 Aug;20(8):1417-28
references.pmid: 19096745
references.citation: Osteoporos Int. 2008 Apr;19(4):503-10
references.pmid: 17929073
references.citation: J Bone Miner Res. 2004 Dec;19(12):2012-20
references.pmid: 15537445
references.citation: Bone. 2009 Sep;45(3):460-5
references.pmid: 19464401
references.citation: Calcif Tissue Int. 2008 Nov;83(5):308-14
references.pmid: 18843436
references.citation: Curr Opin Rheumatol. 2009 Jul;21(4):356-62
references.pmid: 19412103
references.citation: Osteoporos Int. 2009 Apr;20(4):653-64
references.pmid: 18763010
references.citation: Osteoporos Int. 2010 Nov;21(11):1889-97
references.pmid: 19957162
references.citation: Osteoporos Int. 2006 Dec;17(12):1781-93
references.pmid: 17009083
references.citation: Osteoporos Int. 2008 Apr;19(4):399-428
references.pmid: 18266020
references.citation: N Engl J Med. 2004 Jan 29;350(5):459-68
references.pmid: 14749454
references.citation: J Bone Miner Res. 2007 Sep;22(9):1419-25
references.pmid: 17547534
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523
references.pmid: 18254053
references.citation: Br J Pharmacol. 2009 Aug;157(7):1291-300
references.pmid: 19563530
references.citation: Treat Endocrinol. 2006;5(6):347-58
references.pmid: 17107220
references.citation: J Clin Endocrinol Metab. 2007 Aug;92(8):3076-81
references.pmid: 17566094
references.citation: Bone. 2009 Dec;45(6):1059-64
references.pmid: 19679207
references.citation: Osteoporos Int. 2010 Feb;21(2):233-41
references.pmid: 19436941
references.citation: Bone. 2009 May;44(5):744-51
references.pmid: 19130909
references.citation: J Bone Miner Res. 2010 Mar;25(3):455-62
references.pmid: 20201000
references.citation: Menopause. 2009 Mar-Apr;16(2):413-21
references.pmid: 19092711
references.citation: Biochem Biophys Res Commun. 2007 Apr 6;355(2):307-11
references.pmid: 17300752
references.citation: Drugs Today (Barc). 2003 Feb;39(2):89-101
references.pmid: 12698204
references.citation: J Bone Miner Res. 2008 Mar;23(3):433-8
references.pmid: 17997711
references.citation: J Bone Miner Res. 2006 Jul;21(7):1113-20
references.pmid: 16813532
references.citation: Br J Clin Pharmacol. 2008 Nov;66(5):689-94
references.pmid: 18754840
references.citation: Calcif Tissue Int. 2010 Jan;86(1):82-9
references.pmid: 19960189
references.citation: Osteoporos Int. 2009 Jul;20(7):1101-6
references.pmid: 19266136
references.citation: Rheumatol Int. 2010 May;30(7):863-9
references.pmid: 20035331
references.citation: Arthritis Rheum. 2001 Nov;44(11):2611-9
references.pmid: 11710717
references.citation: Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):765-85
references.pmid: 19028356
references.citation: J Bone Miner Res. 2003 Jun;18(6):1082-7
references.pmid: 12817762
references.citation: Biochem Biophys Res Commun. 2004 Oct 29;323(4):1184-90
references.pmid: 15451421
references.citation: Clin Ther. 2005 Apr;27(4):361-76
references.pmid: 15922811
references.citation: Eur J Pharmacol. 2002 Aug 16;450(1):11-7
references.pmid: 12176103
references.citation: Metabolism. 2002 Jul;51(7):906-11
references.pmid: 12077740
references.citation: Curr Med Res Opin. 2007 Dec;23(12):3041-5
references.pmid: 17967221
references.citation: J Bone Miner Res. 1993 May;8(5):607-15
references.pmid: 8511988
references.citation: Osteoporos Int. 2005 Mar;16(3):239-54
references.pmid: 15726235
references.citation: Ann Rheum Dis. 2008 Dec;67(12):1736-8
references.pmid: 18713788
references.citation: Bone. 2003 Jul;33(1):115-23
references.pmid: 12919706
references.citation: Osteoporos Int. 2009 Oct;20(10):1663-73
references.pmid: 19153678
references.citation: J Clin Endocrinol Metab. 2005 May;90(5):2816-22
references.pmid: 15728210
references.citation: Ann Pharmacother. 2007 Jan;41(1):41-5
references.pmid: 17179188
references.citation: J Bone Miner Res. 2008 Feb;23(2):215-22
references.pmid: 17922612
references.citation: Bone. 2008 Jan;42(1):129-38
references.pmid: 17945546
references.citation: Clin Endocrinol (Oxf). 2009 Apr;70(4):522-6
references.pmid: 18625000
references.citation: Drugs Aging. 2008;25(11):963-86
references.pmid: 18947264
references.citation: Bone. 2007 Jan;40(1):218-22
references.pmid: 17010685
references.citation: J Biol Chem. 2009 Jan 2;284(1):575-584
references.pmid: 18927086
references.citation: J Clin Endocrinol Metab. 2002 May;87(5):2060-6
references.pmid: 11994341
references.citation: Horm Metab Res. 2009 Jul;41(7):559-62
references.pmid: 19204890
references.citation: J Cell Mol Med. 2009 Aug;13(8B):2189-99
references.pmid: 20141614
references.citation: Osteoporos Int. 2010 Apr;21(4):667-77
references.pmid: 19597910
references.citation: Ann Rheum Dis. 2008 Mar;67(3):335-9
references.pmid: 17965119
references.citation: Calcif Tissue Int. 2001 Sep;69(3):121-9
references.pmid: 11683526
references.citation: J Clin Invest. 2005 Dec;115(12):3318-25
references.pmid: 16322775
references.citation: Ann Pharmacother. 2006 Jun;40(6):1143-50
references.pmid: 16735667
references.citation: Curr Med Res Opin. 2009 Oct;25(10):2373-87
references.pmid: 19650751
references.citation: Osteoporos Int. 2010 May;21(5):723-32
references.pmid: 19921087
references.citation: J Bone Miner Res. 2009 Aug;24(8):1358-68
references.pmid: 19338452
references.citation: Curr Opin Rheumatol. 2006 Jun;18 Suppl 1:S11-5
references.pmid: 16735840
references.citation: Biochem Pharmacol. 2007 Aug 1;74(3):438-47
references.pmid: 17531955
references.citation: Br Med Bull. 2008;86:129-43
references.pmid: 18477578
references.citation: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326
references.pmid: 16856092
references.citation: Osteoporos Int. 2010 Jun;21(6):1031-6
references.pmid: 19813043
references.citation: Curr Med Res Opin. 2007 Feb;23(2):293-9
references.pmid: 17288683
references.citation: J Bone Miner Res. 2005 Sep;20(9):1569-78
references.pmid: 16059629
references.citation: Bone. 2009 Aug;45(2):200-6
references.pmid: 19376283
references.citation: Drugs Aging. 2007;24(1):37-55
references.pmid: 17233546
references.citation: Osteoporos Int. 2010 Dec;21(12):1993-2002
references.pmid: 20082066
references.citation: Bone. 2010 Apr;46(4):1038-42
references.pmid: 20026265
references.citation: Osteoporos Int. 2010 Jul;21(7):1181-7
references.pmid: 19806285